Skip to search formSkip to main contentSkip to account menu

tovaxin

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Vaccines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design
Background: Tovaxin is an autologous T-cell immunotherapy under investigation for the treatment of MS. The product consists of in… 
2009
2009
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies.
Review
2008
Review
2008
Tovaxin, radiation-attenuated, patient-specific T-cells for the therapeutic vaccination of multiple sclerosis.
Opexa Pharmaceuticals Inc is developing Tovaxin, a trivalent formulation of attenuated myelin-peptide-reactive T-cells, for the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)